DNA Vaccine

Advances in Genetics

Volumn 54, Issue , 2005, Pages 257-289

  Cui, Zhengrong ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; DNA VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; OLIGODEOXYRIBONUCLEOTIDE; VIRUS VACCINE;

ANTIBODY PRODUCTION; AUTOIMMUNITY; CELLULAR IMMUNITY; CLINICAL TRIAL; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PAPILLOMA VIRUS; PLASMID; REVIEW; SAFETY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANTIBODY FORMATION; AUTOIMMUNITY; CANCER VACCINES; CLINICAL TRIALS; HEPATITIS B VACCINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; MALARIA VACCINES; OLIGODEOXYRIBONUCLEOTIDES; PAPILLOMAVIRIDAE; PLASMIDS; SAFETY; VACCINES, DNA; VIRAL VACCINES;

EID: 25144495714     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2660(05)54011-2     Document Type: Review

References (102)

1. Agadjanyan M.G., Kim J.J., Trivedi N., Wilson D.M., Monzavi-Karbassi B., Morrison L.D., Nottingham L.K., Dentchev T., Tsai A., Dang K., Chalian A.A., Maldonado M.A., Williams W.V., and Weiner D.B. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. J. Immunol. 162 (1999) 3417-3427
2. Akira S., Takeda K., and Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nature Immunol. 2 (2001) 675-680
3. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
4. Aliprantis A.O., Yang R.B., Mark M.R., Suggett S., Devaux B., Radolf J.D., Klimpel G.R., Godowski P., and Zychlinsky A. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285 (1999) 736-739
5. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Penninck D., Bronson R., Greene M.F., McClure H.M., Martin L.N., and Ruprecht R.M. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Med. 5 (1999) 194-203
6. Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J.P., van Kooten C., Liu Y.J., Rousset F., and Saeland S. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12 (1994) 881-922
7. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
8. Baud V., Liu Z.G., Bennett B., Suzuki N., Xia Y., and Karin M. Signaling by proinflammatory cytokines: Oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev. 13 (1999) 1297-1308
9. Bender B.S., Ulmer J.B., DeWitt C.M., Cottey R., Taylor S.F., Ward A.M., Friedman A., Liu M.A., and Donnelly J.J. Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice. Vaccine 16 (1998) 1748-1755
10. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., and Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 (1998) 478-480
11. Boyer J.D., Cohen A.D., Vogt S., Schumann K., Nath B., Ahn L., Lacy K., Bagarazzi M.L., Higgins T.J., Baine Y., Ciccarelli R.B., Ginsberg R.S., MacGregor R.R., and Weiner D.B. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J. Infect. Dis. 181 (2000) 476-483
12. Boyle J.S., Silva A., Brady J.L., and Lew A.M. DNA immunization: Iinduction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc. Natl. Acad. Sci. USA 94 (1997) 14626-14631
13. Calarota S.A., Kjerrstrom A., Islam K.B., and Wahren B. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum. Gene Ther. 12 (2001) 1623-1637
14. Castellino F., Zhong G., and Germain R.N. Antigen presentation by MHC class II molecules: Invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Hum. Immunol. 54 (1997) 159-169
15. Chattergoon M.A., Saulino V., Shames J.P., Stein J., Montaner L.J., and Weiner D.B. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine 22 (2004) 1744-1750
16. Chen S.C., Fynan E.F., Robinson H.L., Lu S., Greenberg H.B., Santoro J.C., and Herrmann J.E. Protective immunity induced by rotavirus DNA vaccines. Vaccine 15 (1997) 899-902
17. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C., Greenberg H.B., and Herrmann J.E. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol. 72 (1998) 5757-5761
18. Chen Y., Usherwood E.J., Surman S.L., Hogg T.L., and Woodland D.L. Long-term CD8+ T cell memory to Sendai virus elicited by DNA vaccination. J. Gen. Virol. 80 Pt. 6 (1999) 1393-1399
19. Conry R.M., Curiel D.T., Strong T.V., Moore S.E., Allen K.O., Barlow D.L., Shaw D.R., and LoBuglio A.F. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8 (2002) 2782-2787
20. Corr M., Lee D.J., Carson D.A., and Tighe H. Gene vaccination with naked plasmid DNA: Mechanism of CTL priming. J. Exp. Med. 184 (1996) 1555-1560
21. Cui Z., and Mumper R.J. Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits. Pharm. Res. 19 (2002) 947-953
22. Cui Z., and Mumper R.J. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm. Res. 19 (2002) 939-946
23. Davis H.L., Schirmbeck R., Reimann J., and Whalen R.G. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum. Gene Ther. 6 (1995) 1447-1456
24. Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A., and Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 15 (1997) 71-78
25. Epstein J.E., Charoenvit Y., Kester K.E., Wang R., Newcomer R., Fitzpatrick S., Richie T.L., Tornieporth N., Heppner D.G., Ockenhouse C., Majam V., Holland C., Abot E., Ganeshan H., Berzins M., Jones T., Freydberg C.N., Ng J., Norman J., Carucci D.J., Cohen J., and Hoffman S.L. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 22 (2004) 1592-1603
26. Falo Jr. L.D., Kovacsovics-Bankowski M., Thompson K., and Rock K.L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Med. 1 (1995) 649-653
27. Feltquate D.M., Heaney S., Webster R.G., and Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158 (1997) 2278-2284
28. Freund J. The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review. Am. J. Clin. Pathol. 21 (1951) 645-656
29. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., and Robinson H.L. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 90 (1993) 11478-11482
30. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: Immunology, application, and optimization. Annu. Rev. Immunol. 18 (2000) 927-974
31. Harding C.V., and Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153 (1994) 4925-4933
32. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., Eng J.K., Akira S., Underhill D.M., and Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 (2001) 1099-1103
33. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., Zinkernagel R., and Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nature Med. 10 (2004) 187-192
34. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
35. Herrmann J.E., Chen S.C., Fynan E.F., Santoro J.C., Greenberg H.B., Wang S., and Robinson H.L. Protection against rotavirus infections by DNA vaccination. J. Infect. Dis. 174 Suppl. 1 (1996) S93-S97
36. Herrmann J.E., Chen S.C., Jones D.H., Tinsley-Bown A., Fynan E.F., Greenberg H.B., and Farrar G.H. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 259 (1999) 148-153
37. Hilleman M.R. A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS. Vaccine 16 (1998) 778-793
38. Ichino M., Mor G., Conover J., Weiss W.R., Takeno M., Ishii K.J., and Klinman D.M. Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J. Immunol. 162 (1999) 3814-3818
39. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., and Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158 (1997) 4591-4601
40. Jones D.H., Corris S., McDonald S., Clegg J.C., and Farrar G.H. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 15 (1997) 814-817
41. Kaisho T., and Akira S. Bug detectors. Nature 414 (2001) 701-703
42. Kang Y., Calvo P.A., Daly T.M., and Long C.A. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. J. Immunol. 161 (1998) 4211-4219
43. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., Thatcher J., Weinberg V., Wilson J., Darragh T., Jay N., Da Costa M., and Palefsky J.M. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A phase I study of ZYC101. Clin. Cancer Res. 8 (2002) 1028-1037
44. Klinman D.M., Conover J., and Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 67 (1999) 5658-5663
45. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
46. Kundig T.M., Bachmann M.F., DiPaolo C., Simard J.J., Battegay M., Lother H., Gessner A., Kuhlcke K., Ohashi P.S., Hengartner H., et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268 (1995) 1343-1347
47. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., Kumar S., Wang R., Doolan D.L., Maguire J.D., Parker S.E., Hobart P., Norman J., and Hoffman S.L. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18 (2000) 1893-1901
48. Ledwith B.J., Manam S., Troilo P.J., Barnum A.B., Pauley C.J., Griffiths T.G., 2n., Harper L.B., Schock H.B., Zhang H., Faris J.E., Way P.A., Beare C.M., Bagdon W.J., and Nichols W.W. Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev. Biol. (Basel) 104 (2000) 33-43
49. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., and Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 (1996) 973-983
50. Lesinski G.B., and Westerink M.A. Vaccines against polysaccharide antigens. Curr. Drug Targets Infect. Disord. 1 (2001) 325-334
51. Liu M.A. DNA vaccines: A review. J. Intern. Med. 253 (2003) 402-410
52. Livingston J.B., Lu S., Robinson H., and Anderson D.J. Immunization of the female genital tract with a DNA-based vaccine. Infect. Immun. 66 (1998) 322-329
53. Lundholm P., Asakura Y., Hinkula J., Lucht E., and Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 17 (1999) 2036-2042
54. MacGregor R.R., Boyer J.D., Ciccarelli R.B., Ginsberg R.S., and Weiner D.B. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: Follow-up data. J. Infect. Dis. 181 (2000) 406
55. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., Chattergoon M.A., Baine Y., Higgins T.J., Ciccarelli R.B., Coney L.R., Ginsberg R.S., and Weiner D.B. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J. Infect. Dis. 178 (1998) 92-100
56. MacGregor R.R., Ginsberg R., Ugen K.E., Baine Y., Kang C.U., Tu X.M., Higgins T., Weiner D.B., and Boyer J.D. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. Aids 16 (2002) 2137-2143
57. Martin T., Parker S.E., Hedstrom R., Le T., Hoffman S.L., Norman J., Hobart P., and Lew D. Plasmid DNA malaria vaccine: The potential for genomic integration after intramuscular injection. Hum. Gene Ther. 10 (1999) 759-768
58. Martins L.P., Lau L.L., Asano M.S., and Ahmed R. DNA vaccination against persistent viral infection. J. Virol. 69 (1995) 2574-2582
59. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Roy M., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., and Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Med. 9 (2003) 729-735
60. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 10 (1992) 75-88
61. Medzhitov R. Toll-like receptors and innate immunity. Nature Rev. Immunol. 1 (2001) 135-145
62. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997) 394-397
63. Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C., Ghosh S., and Janeway Jr. C.A. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2 (1998) 253-258
64. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., Georgiev G., Petrov S., and Meryman H.T. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur. Urol. 38 (2000) 208-217
65. Moorthy V.S., Pinder M., Reece W.H., Watkins K., Atabani S., Hannan C., Bojang K., McAdam K.P., Schneider J., Gilbert S., and Hill A.V. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J. Infect. Dis. 188 (2003) 1239-1244
66. Mor G., Yamshchikov G., Sedegah M., Takeno M., Wang R., Houghten R.A., Hoffman S., and Klinman D.M. Induction of neonatal tolerance by plasmid DNA vaccination of mice. J. Clin. Invest. 98 (1996) 2700-2705
67. Muzio M., Natoli G., Saccani S., Levrero M., and Mantovani A. The human toll signaling pathway: Divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 187 (1998) 2097-2101
68. Park J.S., Oh Y.K., Kang M.J., and Kim C.K. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J. Med. Virol. 70 (2003) 633-641
69. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282 (1998) 2085-2088
70. Raychaudhuri S., and Rock K.L. Fully mobilizing host defense: Building better vaccines. Nature Biotechnol. 16 (1998) 1025-1031
71. Raz E., Carson D.A., Parker S.E., Parr T.B., Abai A.M., Aichinger G., Gromkowski S.H., Singh M., Lew D., Yankauckas M.A., et al. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc. Natl. Acad. Sci. USA 91 (1994) 9519-9523
72. Ridge J.P., Di Rosa F., and Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393 (1998) 474-478
73. Rosenberg S.A., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., and White D.E. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum. Gene Ther. 14 (2003) 709-714
74. Roy K., Mao H.Q., Huang S.K., and Leong K.W. Oral gene delivery with chitosan: DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Med. 5 (1999) 387-391
75. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., Culp J., Burkholder J.K., Swain W.F., Dixon R.M., Widera G., Vessey R., King A., Ogg G., Gallimore A., Haynes J.R., and Heydenburg Fuller D. Induction of antigen-specific CD8+ T-Cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 (2000) 764-778
76. Russell-Jones G.J. Oral vaccine delivery. J. Control Release 65 (2000) 49-54
77. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
78. Segal B.M., Klinman D.M., and Shevach E.M. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol. 158 (1997) 5087-5090
79. Shimada S., Yano O., Inoue H., Kuramoto E., Fukuda T., Yamamoto H., Kataoka T., and Tokunaga T. Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J. Natl. Cancer Inst. 74 (1985) 681-688
80. Stein D., Roth S., Vogelsang E., and Nusslein-Volhard C. The polarity of the dorsoventral axis in the Drosophila embryo is defined by an extracellular signal. Cell 65 (1991) 725-735
81. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., and Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17 (1999) 2826-2829
82. Tagawa S.T., Lee P., Snively J., Boswell W., Ounpraseuth S., Lee S., Hickingbottom B., Smith J., Johnson D., and Weber J.S. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 98 (2003) 144-154
83. Takashima A., and Morita A. Dendritic cells in genetic immunization. J. Leukocyte Biol. 66 (1999) 350-356
84. Tang D.C., DeVit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 (1992) 152-154
85. Tang D.C., Shi Z., and Curiel D.T. Vaccination onto bare skin. Nature 388 (1997) 729-730
86. Timmerman J.M., Singh G., Hermanson G., Hobart P., Czerwinski D.K., Taidi B., Rajapaksa R., Caspar C.B., Van Beckhoven A., and Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62 (2002) 5845-5852
87. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T., et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72 (1984) 955-962
88. Tokunaga T., Yamamoto T., and Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn. J. Infect. Dis. 52 (1999) 1-11
89. Torres C.A., Iwasaki A., Barber B.H., and Robinson H.L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 158 (1997) 4529-4532
90. Ugen K.E., Nyland S.B., Boyer J.D., Vidal C., Lera L., Rasheid S., Chattergoon M., Bagarazzi M.L., Ciccarelli R., Higgins T., Baine Y., Ginsberg R., Macgregor R.R., and Weiner D.B. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 16 (1998) 1818-1821
91. Ulmer J.B., Deck R.R., Dewitt C.M., Donnhly J.I., and Liu M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: Antigen presentation by non-muscle cells. Immunology 89 (1996) 59-67
92. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
93. Underhill D.M., Ozinsky A., Hajjar A.M., Stevens A., Wilson C.B., Bassetti M., and Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401 (1999) 811-815
94. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., Jones T.R., Hobart P., Margalith M., Ng J., Weiss W.R., Sedegah M., de Taisne C., Norman J.A., and Hoffman S.L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476-480
95. Wang R., Epstein J., Charoenvit Y., Baraceros F.M., Rahardjo N., Gay T., Banania J.G., Chattopadhyay R., de la Vega P., Richie T.L., Tornieporth N., Doolan D.L., Kester K.E., Heppner D.G., Norman J., Carucci D.J., Cohen J.D., and Hoffman S.L. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J. Immunol. 172 (2004) 5561-5569
96. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., Harper L.B., Pauley C.J., Niu Z., Denisova L., Follmer T.T., Rizzuto G., Ciliberto G., Fattori E., Monica N.L., Manam S., and Ledwith B.J. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 11 (2004) 711-721
97. Weber R., Bossart W., Cone R., Luethy R., and Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Eur. J. Clin. Microbiol. Infect. Dis. 20 (2001) 800-803
98. Wesche H., Korherr C., Kracht M., Falk W., Resch K., and Martin M.U. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J. Biol. Chem. 272 (1997) 7727-7731
99. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., and Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 247 (1990) 1465-1468
100. Yamamoto S., Kuramoto E., Shimada S., and Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. 79 (1988) 866-873
101. Zarember K.A., and Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168 (2002) 554-561
102. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., and Ghosh S. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303 (2004) 1522-1526